Teclistamab or Talquetamab in Combination With Daratumumab for High-Risk Smoldering Myeloma (REVIVE Study)

Conditions: Multiple Myeloma Interventions: Drug: Teclistamab; Drug: Talquetamab; Drug: Daratumumab SC Sponsors: University of Miami; Janssen Scientific Affairs, LLC Not yet recruiting

https://clinicaltrials.gov/study/NCT06100237

Source: ClinicalTrials.gov - October 25, 2023 Category: Research Source Type: clinical trials

More News: Myeloma | Research | Study